Literature DB >> 19020842

Isolation of drug-resistant mutant HIV variants using tissue culture drug selection.

Maureen Oliveira1, Bluma G Brenner, Mark A Wainberg.   

Abstract

The life cycle of HIV-1 can be affected in different manners by the various classes of antiviral agents. Genetic heterogeneity is a characteristic of this virus, which contributes significantly to the ability of the virus to generate mutations which overcome the efficacy of the drug therapy. The selection of drug resistant mutants in vitro can be readily accomplished by maintaining the virus in a state of sub-optimal growth, regulated by slowly increasing the amount of drug pressure applied. This technique is thought to mimic the consequences of drug therapy in patients. Therefore, in this way, novel compounds can be assessed for their selection profile in order to preview the likelihood of emergence of HIV-1 drug resistance in future clinical trials. In addition, combinations of drugs can be investigated in the same manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19020842     DOI: 10.1007/978-1-59745-170-3_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

2.  Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Peter K Quashie; Matthew McCallum; Yingshan Han; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Authors:  Peter K Quashie; Thibault Mesplède; Ying-Shan Han; Maureen Oliveira; Diane N Singhroy; Tamio Fujiwara; Mark R Underwood; Mark A Wainberg
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

4.  Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Wei Huang; Maureen Oliveira; Yingshan Han; Yudong Quan; Christos J Petropoulos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Authors:  Said A Hassounah; Yannan Liu; Peter K Quashie; Maureen Oliveira; Daniela Moisi; Bluma G Brenner; Paul A Sandstrom; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

6.  Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

Authors:  Tamara Bar-Magen; Richard D Sloan; Daniel A Donahue; Björn D Kuhl; Alexandra Zabeida; Hongtao Xu; Maureen Oliveira; Daria J Hazuda; Mark A Wainberg
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Eugene L Asahchop; Matthew McCallum; Peter K Quashie; Yingshan Han; Yudong Quan; Mark A Wainberg
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

8.  Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.

Authors:  Eugene L Asahchop; Maureen Oliveira; Mark A Wainberg; Bluma G Brenner; Daniela Moisi; Thomas d'Aquin Toni; Cecile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

9.  Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.

Authors:  Kaitlin Anstett; Thibault Mesplede; Maureen Oliveira; Vincent Cutillas; Mark A Wainberg
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

10.  The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Yingshan Han; Yudong Quan; Veronica Zanichelli; Mark A Wainberg
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.